Clinical Trial Update: IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion [NA]

View source ↗

Summary

Clinical trial comparing adrenalectomy to semaglutide for metabolic outcomes in patients with Mild Autonomous Cortisol Secretion (MACS), currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Subclinical Cushing Syndrome

Drugs mentioned

• semaglutide (semaglutide)

Snippet

Sponsor: University of Texas Southwestern Medical Center | Conditions: Mild Autonomous Cortisol Secretion (MACS), Autonomous Cortisol Secretion (ACS) | NA | Status: RECRUITING